William Blair analyst Matt Larew has maintained their bullish stance on WST stock, giving a Buy rating on July 15.

Claim 55% Off TipRanks

• Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
• Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Matt Larew has given his Buy rating due to a combination of factors, including West’s ability to deliver another quarter of solid double-digit organic growth, driven largely by strong momentum in its biologics franchise. He highlights that both GLP and non-GLP products are contributing meaningfully, with non-GLP offerings growing at a high-teens rate and GLP-1–related products already representing a notable share of total company revenue.

Larew also points to the company’s top-line results, which exceeded both his and the Street’s expectations, as well as the improved margins and earnings per share performance that underscore operating leverage. In his view, the revised full-year outlook retains an element of conservatism despite a strong first half, leaving room for upside if demand for West’s elastomer and West Vantage solutions continues to track ahead of plan.

According to TipRanks, Larew is a 4-star analyst with an average return of 10.0% and a 53.13% success rate. Larew covers the Healthcare sector, focusing on stocks such as West Pharmaceutical Services, Option Care Health, and Repligen.

In another report released on July 15, TD Cowen also maintained a Buy rating on the stock with a $410.00 price target.